Company intelligence / Profile preview

Knoubis Bio, Inc.

La Jolla, California, United Statesknoubisbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Knoubis Bio develops first-in-class phosphatase-targeting biologics aimed at innovative therapies. The company was founded in 2022 and has received early-stage funding awards. Its lead program appears to target synoviocytes for potential treatment of joint-related diseases. No clinical results have been published yet.[1][2][3][4][5]

Therapeutic areas: Rheumatology
Modalities: Biologics (specifically phosphatase-targeting biologics)[3]
Industry: Biotech

Partnerships

Harrington Discovery Institute collaboration/co-founding support[4]

Beyond the preview

Go deeper on Knoubis Bio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Knoubis Bio, Inc..

Explore the full profile